You are here: Industry Insights > biosimilars

News List

Which of the Blockbuster Drugs on the Autoimmune Drug Market Will Show the Glory that Humira Had?(2) Siyi
June 06, 2018
Enbrel and Remicade have begun to suffer impacts of generic drugs, with market shares largely reducing.
Oral Biologics Delivery Could Be The Key For Biosimilars To Gain Market Share From Blockbuster Drugs biospace
April 25, 2018
Frost & Sullivan today announced the results of a research study that points the way for biosimilar companies to take market share from blockbuster drugs, and for pharmaceutical companies with blockbusters to protect their position
FDA Issues CLRs for Two Celltrion and Teva Biosimilars biospace
April 08, 2018
The U.S. Food and Drug Administration (FDA) issued two Complete Response Letters (CRLs) to South Korean manufacturer Celltrion.
Current Situation of Biosimilars in China III: Analysis of Biosimilars of Five Blockbusts Tang
January 16, 2018
The biosimilars in China just started, and the biosimilar review and approval policies continue to be improved.
Current Situation of Biosimilars in China II: 2016-2020 will be the Prime Time of Biosimilars Tang
January 15, 2018
The Chinese biosimilar market can reach RMB 20-30 billion in 2020...
Momenta and Mylan Announce Development Strategy for M710, a Proposed Biosimilar to EYLEA (aflibercep biospace
January 05, 2018
Momenta Pharmaceuticals and Mylan Corporation today announced the M710 development strategy, the biosimilars EYLEA® injection.
Mylan-Biocon’s breast cancer biosimilar gets ANVISA nod expressbpd
January 02, 2018
Biocon and Mylan’s proposed biosimilar trastuzumab has been approved by Brazilian regulatory agency ANVISA, through their partner Libbs Farmaceutica (Libbs).
Biocon and Mylan's Biosimilar Trastuzumab Receives Approval From ANVISA, Brazil Through Their Partne biospace
January 02, 2018
Biosimilar Trastuzumab, developed jointly by BIOCON Ltd. and Mylan NV, has been approved by the Brazilian regulator ANVISA through its partner Libbs Farmaceutica (Libbs), a leading Brazilian pharmaceutical company.
Dr. Reddy's launches Melphalan Hydrochloride for Injection in the U.S. Market biospectrumasia
December 28, 2017
According to IMS Health data, The Alkeran® brand and generic had U.S. sales of approximately $107 million MAT for the most recent twelve months ending in October 2017
Current Situation of Biosimilars in China III: Analysis of Biosimilars of Five Blockbust Tang
December 27, 2017
The biosimilars in China just started, and the biosimilar review and approval policies continue to be improved.

Previous page 1 2 3 4 5 6 Next page